Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
August 2023
-
Statement
Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Media Release
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six… -
Media Release
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Sandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly… -
Media Release
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Biosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients… -
Key Release
Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
Ad hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus… -
Key Release
Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
Ad-hoc-Meldung nach Art. 53 LR Einladung zur ausserordentlichen Generalversammlung von Novartis am 15. September 2023 und Informationsbroschüre für Aktionärinnen und Aktionäre publiziertSandoz… -
Key Release
Novartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
Annonce ad hoc en vertu de l’art. 53 LR Invitation à l’assemblée générale extraordinaire de Novartis du 15 septembre 2023 et publication d’une brochure d’information destinée… -
Media Release
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading… -
Media Release
Novartis completes acquisition of Chinook Therapeutics
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin… -
Key Release
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across… -
Statement
European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)